A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata
In the register
The register attaches this trial to Upadacitinib (Rinvoq) (AbbVie), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 3
- Sponsor
- AbbVie
- Participants (registry)
- 1500
- Start
- October 2023
- Primary completion
- April 2030 (planned)
- Study completion
- April 2030 (planned)
- Last registry update
- August 2026
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, France, Germany, Greece, Hungary, Israel, Italy, Japan, New Zealand, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey, United Kingdom
Conditions studied: Alopecia Areata
Interventions: Upadacitinib, Rinvoq, ABT-494, Placebo
Other trials of Upadacitinib (Rinvoq)
- NCT04159597Available (expanded access)
Expanded Access to Upadacitinib
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.